Bond.az White LogoBond.az Black Logo

JPMorgan raises Fibra Uno price target on NEXT

JPMorgan raised Fibra Uno's price target to Peso36, citing NEXT consolidation and internalization. The stock offers a 9.61% dividend yield.

Robert Moore
ByRobert Moore- Senior Editor
|
0

JPMorgan raised its price target on Fibra Uno Administracion SA de CV (FUNO11:MM) to Peso36.00 from Peso33.00 while maintaining an Overweight rating. The REIT currently trades at a P/E ratio of 4.57 and maintains a market capitalization of $6.42 billion.

The firm raised its estimates to reflect the full consolidation of Fibra NEXT and the financial effects of the advisor internalization completed in the fourth quarter of 2025. NEXT's contribution is the primary growth driver and more than offsets the income lost from three properties transferred as payment for the internalization.

The transferred properties include Samara, Midtown Jalisco, and Montes Urales 620, totaling approximately 260,000 square meters of gross leasable area. JPMorgan estimates approximately Peso250 million of revenues were foregone from the internalization assets in the first quarter versus approximately Peso550 million from NEXT.

The firm revised its top-line growth estimates to 6% and 13% for 2026 and 2027, respectively, implying year-over-year growth of 10% and 11%. Positive leasing spreads in industrial and retail and inflation-driven rent escalations support the revised growth.

JPMorgan noted the stock trades at approximately 40% discount to net asset value and offers a 9.5% dividend yield for 2026. According to Bond.az data, the company currently offers a 9.61% dividend yield and has maintained dividend payments for 16 consecutive years. Bond.az analysis indicates the stock is undervalued based on its Fair Value assessment. The firm identified Fibra Uno as its top pick in the Mexico real estate space together with Vesta.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

More News
Today / 13:01
|
953

UBS Upgrades Vipshop on Earnings

UBS upgrades Vipshop stock to Buy, cuts target to $18.50. Vipshop trades at 6x P/E with strong cash position and 4.16% dividend yield.

0
Today / 13:00
|
675

BofA Initiates Pershing Square Stock with Neutral Rating

BofA Securities starts Pershing Square with Neutral rating and $42 target. Analysis highlights unique fee structure and strong performance.

0
2026-05-22 14:25
|
910

Benchmark cuts Lightspeed stock price target

Benchmark cuts Lightspeed price target to $16, maintains Buy. LSPD shares trade at $8.57 with a market cap of $1.18B.

0
2026-05-22 14:23
|
696

Benchmark Reiterates NetEase Buy

Benchmark reiterates Buy on NetEase after strong Q1 results, citing AI integration and margin expansion.

0
2026-05-22 14:21
|
911

Benchmark Reaffirms Spotify Stock Rating

Benchmark reaffirms Buy rating on Spotify stock with $695 target, citing engagement monetization strategy. Spotifys financial health and Audiobooks Plus success highlighted.

0
2026-05-22 14:04
|
264

Keefe Bruyette Reiterates Progressive Stock Rating at Market Perform

Keefe, Bruyette & Woods reiterates Market Perform rating on Progressive stock with $208 price target.

0
2026-05-22 14:03
|
304

Datadog stock Buy rating reaffirmed

DA Davidson reaffirms Datadog Buy rating with $250 target, citing AI positioning and long-term growth.

0
2026-05-22 13:31
|
725

Generac Stock Upgrade: Data Center Outlook

Jefferies upgrades Generac stock to Buy, citing data center prospects. Target price raised to $302. Stock up 100% in a year.

0
2026-05-22 12:50
|
462

KeyBanc Reiterates Overweight on Walmart, $145 Target

KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.

0
2026-05-22 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
2026-05-22 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
2026-05-22 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
...